About Imbio
Imbio is a company based in Minneapolis (United States) founded in 2005 was acquired by 4DMedical in December 2023.. Imbio has raised $2.58 million across 10 funding rounds from investors including HHS, 4DMedical and Invenshure. Imbio offers products and services including Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification. Imbio operates in a competitive market with competitors including ArtiQ, Sime Dx, FibroNest, Echoliv and SonmolTech, among others.
- Headquarter Minneapolis, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Imbio, Llc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Imbio
Imbio offers a comprehensive portfolio of products and services, including Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI software for quantifying lung density in medical images.
AI tool for assessing lung texture and function patterns.
Software for evaluating hypertension in pulmonary arteries.
AI system for analyzing airway structures in images.
AI tool for detecting calcification in coronary arteries.
Unlock access to complete
Unlock access to complete
Funding Insights of Imbio
Imbio has successfully raised a total of $2.58M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $249.01 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Grant — $249,008
-
First Round
First Round
(20 Sep 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Grant - Imbio | Valuation |
investors |
|
| May, 2019 | Amount | Grant - Imbio | Valuation |
investors |
|
| Aug, 2018 | Amount | Grant - Imbio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Imbio
Imbio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, 4DMedical and Invenshure. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Invenshure is focused on building companies from institutional IP.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Manufacturer of respiratory imaging and ventilation analysis equipment
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Imbio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Imbio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Imbio Comparisons
Competitors of Imbio
Imbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArtiQ, Sime Dx, FibroNest, Echoliv and SonmolTech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-powered software to optimize clinical trials and enhance diagnostic processes
|
|
| domain | founded_year | HQ Location |
Point-of-care digital diagnostics are developed and provided by Sime Dx.
|
|
| domain | founded_year | HQ Location |
AI tools for quantifying fibrosis and inflammation in medical images for drug development.
|
|
| domain | founded_year | HQ Location |
AI-based tool for liver cancer diagnosis is provided to providers.
|
|
| domain | founded_year | HQ Location |
SonmolTech is engaged in developing respiratory care technology solutions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Imbio
Frequently Asked Questions about Imbio
When was Imbio founded?
Imbio was founded in 2005 and raised its 1st funding round 8 years after it was founded.
Where is Imbio located?
Imbio is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Is Imbio a funded company?
Imbio is a funded company, having raised a total of $2.58M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.72M, raised on Sep 20, 2013.
What does Imbio do?
Imbio is a medical imaging company that develops clinical decision-support solutions using big data and medical image analysis. The companys current offerings are focused on 3D visualization and automated analysis of respiratory system images derived from CT scans. These include CE marked Functional Lung Density Analysis (fLDA) tests (a fully-automated image analysis system that provides a complete mapping of normal lung, air trapping, and areas of persistent low density in a combined image to help visualize the components of COPD), and LDA for Inspiration Analysis for Lung Screening and basic COPD assessment (test to identify and quantify emphysema), and Lung Texture Analysis using High Resolution CT images (for visualization, detection and quantification of lung fibrosis). The company has also developed investigationalresearch tools for airway analysis (analysis of airway remodelling, a characteristic feature of many lung diseases), computer-aided nodule assessment and risk yield (also called CANARY, this is a non-invasive imaging technique licensed from the Mayo Clinic, to risk stratify adenocarcinoma) and RVLV analysis to predict short-term mortality and adverse clinical events in patients with acute pulmonary embolism.
What products or services does Imbio offer?
Imbio offers Lung Density Analysis, Functional Lung Texture Analysis, Pulmonary Hypertension Assessment, Airway Analysis, and Coronary Calcification.
Who are Imbio's investors?
Imbio has 3 investors. Key investors include HHS, 4DMedical, and Invenshure.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.